Trial · NCT07900256
A Preliminary Exploratory Study of Cadonilimab Combined With Progestin for Fertility-Sparing Treatment in Early Endometrial Cancer
NCT07900256, Phase 2, Not yet recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Preliminary Exploratory Study of Cadonilimab Combined With Progestin for Fertility-Sparing Treatment in Early Endometrial Cancer. Trials, record NCT07900256. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07900256
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Preliminary Exploratory Study of Cadonilimab Combined With Progestin for Fertility-Sparing Treatment in Early Endometrial Cancer
- NCT number
- NCT07900256
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 10 participants, estimated
- Lead sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Conditions
- Endometrial Cancer
- Interventions
- Cadonilimab, Megestrol Acetate (MA), Levonorgestrel-releasing intrauterine system
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete Response Rate (CRR) | Up to 6 months after treatment initiation | The proportion of participants who achieve pathological complete response (CR), defined as no evidence of endometrial cancer or atypical hyperplasia on histopathological examination of endometrial tissue obtained by hysteroscopy-guided endometrial biopsy. |
| Primary | Duration of Complete Response (DOR) | From the date of first documented CR until disease recurrence, progression, or the last follow-up, up to 36 months. | The time from the date of first documented pathological complete response (CR) to disease recurrence, disease progression, or the last follow-up. |
| Secondary | Pregnancy Rate | From treatment completion through follow-up, up to 24 months. | The proportion of participants attempting conception who achieve a pregnancy lasting more than 12 weeks after treatment. |
| Secondary | Live Birth Rate | From treatment completion through follow-up, up to 36 months. | The proportion of participants who achieve pregnancy and subsequently deliver a live-born infant. |
| Secondary | Recurrence Rate | From the date of first documented complete response until recurrence or the last follow-up, up to 36 months. | The proportion of participants who achieve complete response and subsequently develop histologically confirmed recurrence of endometrial cancer or atypical hyperplasia, or new pelvic or extra-pelvic lesions on imaging. |
| Secondary | Incidence of Adverse Events | From treatment initiation through the end of the treatment period, up to 6 months. | The incidence, type, and severity of adverse events, serious adverse events, immune-related adverse events, and progestin-related adverse reactions will be assessed and graded according to CTCAE. |
| Secondary | Changes in Serum Tumor Markers | Baseline and during treatment, up to 6 months. | Changes in serum tumor marker levels, such as CA125, from baseline to post-treatment assessment will be evaluated. |
| Other | Changes in Pathological Biomarkers | Baseline and during treatment, up to 6 months. | Changes in the expression of Ki-67, estrogen receptor (ER), progesterone receptor (PR), and PD-L1 from baseline to post-treatment assessment will be evaluated. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07900256
GET https://conductscience.org/api/trials/v1/NCT07900256/registered